We found that the pre-selection of CRC tumors for their KRAS, NRAS, BRAF, and PI3K wildtype status efficiently selected anti-EGFR sensitive tumors in the majority of PDX models tested (15/21). The gene discussed is BRAF; the disease is colorectal carcinoma.